Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDH.L Regulatory News (IDH)

  • There is currently no data for IDH

Acquisition & Research Agreement

13 Sep 2010 07:00

RNS Number : 5363S
Immunodiagnostic Systems Hldgs PLC
13 September 2010
 



Immunodiagnostic Systems Holdings plc

 

Acquisition and Research Agreement

 

Immunodiagnostic Systems Holdings plc ("IDS"), a leading producer of diagnostic testing kits for the clinical and research markets, announces that it has acquired 100% of the share capital of MGP Diagnostics AS of Mjøndalen, Norway (MGPD) for an undisclosed cash consideration.

 

MGPD is a non-trading company owning a portfolio of patents relating to the determination of a unique biomarker called Matrix GLA protein (mGLA). There is growing evidence that mGLA is a controlling factor in the inappropriate calcification of soft tissues such as the carotid arteries and heart valves, with an increasing number of publications appearing in the scientific literature in recent years.

 

Vascular calcification is known to play a significant role in the development of cardiovascular disease (CVD). It is particularly common in patients suffering from chronic kidney disease (CKD) and those on kidney dialysis, who commonly develop bone disease as a result of their failing kidneys. More than 80% of dialysis patients develop some degree of coronary artery calcification.

 

IDS also announces that it has entered into a Research Agreement with VitaK BV of Maastricht in the Netherlands. VitaK is the leading research establishment in mGLA biology in the world, having filed the original patents now acquired by IDS from MGPD. IDS and VitaK will work closely to accelerate the proof of concept studies needed to establish the clinical utility of mGLA.

 

Dr Roger Duggan, CEO of IDS, commented: "This acquisition provides IDS with an IP-protected entry into an adjacent, highly complementary area of potential clinical importance. Calcification of bones and teeth is highly desirable, but in soft tissues such as arteries and heart valves is potentially lethal. The future availability of a serum biomarker for early diagnosis and the monitoring of therapy will provide a valuable tool to cardiovascular and renal physicians throughout the world."

 

For further information:

 

Immunodiagnostic Systems Holdings PLC

Tel: 0191 519 0660

Roger Duggan, CEO

Ian Cookson, COO

Paul Hailes, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8787

Paul McManus

Mob: 07980 541 893

paul.mcmanus@walbrookpr.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKKBDBDBKDNCD
Date   Source Headline
28th Jun 201612:29 pmRNSDirector/PDMR Shareholding
23rd Jun 20161:42 pmRNSDirector/PDMR Shareholding
22nd Jun 20167:45 amRNSAnnual Report and Accounts
22nd Jun 20167:00 amRNSPreliminary Results
9th Jun 20167:00 amRNSUpdate re Royalty Revenues
20th May 20169:20 amRNSHolding(s) in Company
6th May 201610:30 amRNSLaunch of IDS-iSYS 17-OH Progesterone assay
25th Apr 20167:00 amRNSFull Year Trading Update
8th Jan 20167:00 amRNSRelocation of Automated related Assay Activity
4th Jan 20167:30 amRNSPaul Martin joins as Group Finance Director
18th Dec 20159:43 amRNSLaunch of Salivary Cortisol Hypertension Assay
30th Nov 201510:41 amRNSHolding(s) in Company
24th Nov 20157:00 amRNSHalf Yearly Report
22nd Oct 20152:22 pmRNSDirectorate Change
21st Oct 20155:00 pmRNSHolding(s) in Company - Replacement
20th Oct 20152:23 pmRNSDirectorate Change
13th Oct 20157:00 amRNSTrading Statement
8th Oct 20154:40 pmRNSHolding(s) in Company
1st Oct 201512:05 pmRNSTotal Voting Rights
30th Sep 20152:05 pmRNSHolding(s) in Company
15th Sep 20154:32 pmRNSAdditional Listing
4th Aug 20152:43 pmRNSResult of AGM
4th Aug 20157:00 amRNSAGM Statement
29th Jun 20153:18 pmRNSRe Report and Accounts and AGM - Replacement
29th Jun 201511:59 amRNSRe Report and Accounts and AGM
29th Jun 20157:15 amRNSDirectorate Change
23rd Jun 20157:00 amRNSFinal Results
12th Jun 20154:00 pmRNSBoard Appointment
10th Jun 20157:00 amRNSDirectorate Change
29th May 20157:00 amRNSTrading Statement
21st Apr 20157:00 amRNSTrading Statement
2nd Apr 20157:43 amRNSPatricio Lacalle Joins as Chief Executive Officer
9th Feb 201510:30 amRNSHolding(s) in Company
3rd Feb 20157:00 amRNSDirectorate Change
6th Jan 20155:04 pmRNSAdditional Listing
5th Jan 20155:10 pmRNSAdditional Listing
24th Dec 20141:30 pmRNSDirectorate Change
19th Dec 201410:47 amRNSHolding(s) in Company
19th Dec 20148:40 amRNSHolding(s) in Company
18th Dec 20149:30 amRNSDirector/PDMR Shareholding
15th Dec 20145:13 pmRNSHolding(s) in Company
12th Dec 20147:00 amRNSLaunch of 1,25-Dihydroxy Vitamin D Assay
8th Dec 20143:38 pmRNSHolding(s) in Company
4th Dec 20145:36 pmRNSDirectorate Change
4th Dec 20144:27 pmRNSDirector/PDMR Shareholding
25th Nov 20147:00 amRNSDirectorate Change
25th Nov 20147:00 amRNSHalf Yearly Report
24th Nov 20145:20 pmRNSPatrik Dahlen Resigns as CEO
14th Oct 20147:00 amRNSTrading Update
15th Sep 20147:00 amRNSUpdate on current trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.